Table 1. Results of 6 years testosterone administration to men with late-onset hypogonadism, ≤65 years of age (young) and >65 years (old).
| Variable | Young (n=450) | Old (n=111) | ||||
|---|---|---|---|---|---|---|
| Baseline, mean±SD | 6 Years, mean±SD | Change, mean±SE | Baseline, mean±SD | 6 Years, mean±SD | Change, mean±SE | |
| Age (y), mean±SD (range) | 56.10±6.29 (32-65) | 68.45±2.91 (66-84) | ||||
| Anthropometry | ||||||
| Weight (kg) | 102.52±15.56 | 90.15±9.69 | -14.78±0.35a | 102.83±15.64 | 95.35±9.03 | -15.14±0.71a |
| Body mass index (kg/m2) | 32.58±5.08 | 29.02±3.02 | -4.72±0.11a | 32.84±4.86 | 30.35±2.61 | -4.81±0.22a |
| Weight loss (%) | - | 13.56±7.56a | - | - | 13.28±7.14a | - |
| Waist circumference (cm) | 106.54±9.03 | 98.26±7.1 | -9.34±0.2a | 108.95±10.75 | 100.72±9.45 | -10.45±0.47a |
| Testosterone (nmol/L) | 8.96±1.95 | 17.33±2.39 | 8.22±0.19a | 8.48±2.26 | 17.12±1.78 | 8.98±0.47a |
| Prostate parameters | ||||||
| Prostate volume (mL) | 26.77±9.5 | 31.58±10.9 | 2.77±0.16a | 33.85±8.67 | 39.95±7.6 | 3.37±0.36a |
| PSA (ng/mL) | 1.33±0.91 | 1.65±0.83 | 0.36±0.02a | 1.44±0.98 | 1.88±0.84 | 0.38±0.05a |
| Urinary function | ||||||
| Residual voiding volume (mL) | 34.87±23.16 | 16.72±6.74 | -22.17±0.73a | 41.46±23.48 | 27.25±1.58 | -18.84±5.76a |
| IPSS | 7.74±5.00 | 3.89±3.12 | -4.4±0.15a | 10.7±4.07 | 4.63±2.63 | -5.89±0.30a |
| IIEF-EF | 14.94±7.34 | 24.21±4.39 | 8.53±0.26a | 11.87±7.58 | 22.12±6.41 | 8.12±0.59a |
| Quality of life, AMS | 53.53±9.47 | 21.68±6.88 | -32.01±0.49a | 54.99±9.02 | 23.45±7.91 | -31.57±0.98a |
| Glycemic control | ||||||
| Fasting glucose (mg/dL) | 104.18±22.17 | 96.44±8.44 | -7.57±1.01a | 119.07±40.01 | 101.74±19.37 | -19.21±3.64a |
| HbA1c (%) | 6.64±1.32 | 5.66±0.65 | -1.15±0.04a | 7.00±1.38 | 5.94±0.82 | -1.37±0.09a |
| Lipids | ||||||
| Total cholesterol (mg/dL) | 268.92±45.95 | 193.56±16.58 | -76.89±2.3a | 268.44±52.69 | 191.69±21.8 | -82.55±5.66a |
| HDL (mg/dL) | 48.91±17.33 | 59.55±17.66 | 11.99±0.66a | 51.64±16.56 | 61.99±16.87 | 9.15±1.75a |
| LDL (mg/dL) | 159.87±36.70 | 119.81±34.87 | -34.63±1.62a | 162.48±31.63 | 120.86±33.56 | -40.25±3.58a |
| Triglycerides (mg/dL) | 262.35±73.16 | 192.10±34.40 | -71.04±3.64a | 266.9±84.37 | 192.27±32.16 | -98.3±8.12a |
| Ratio total cholesterol: HDL | 6.15±2.42 | 3.54±1.04 | -2.78±0.10a | 5.67±2.09 | 3.32±0.91 | -2.4±0.2a |
| Erythropoiesis/blood count | ||||||
| Hemoglobin (g/dL) | 14.39±0.89 | 15.13±0.52 | 0.77±0.05a | 14.09±1.16 | 15.12±0.81 | 1.06±0.14a |
| Hematocrit (%) | 42.98±3.27 | 48.42±2.25 | 5.56±0.21a | 42.71±3.67 | 48.58±2.28 | 5.76±0.50a |
| Leukocytes (109/L) | 7.38±2.48 | 6.29±0.83 | -0.45±0.14a | 7.08±2.02 | 6.3±0.87 | -0.8±0.26b |
| Liver transaminases | ||||||
| AST (U/L) | 35.80±16.04 | 22.83±6.43 | -12.41±0.84a | 31.33±14.71 | 22.39±6.47 | -8.8±2.03a |
| ALT (U/L) | 38.17±18.92 | 24.64±10.66 | -11.91±1.05a | 37.5±22.77 | 24.73±9.52 | -11.71±2.63a |
| Inflammation, CRP (mg/dL) | 4.04±6.34 | 0.75±1.06 | -3.49±0.22a | 2.65±3.75 | 0.71±0.51 | -2.5±0.29a |
| Blood pressure | ||||||
| Systolic (mmHg) | 145.51±17.73 | 132.39±10.41 | -17.21±0.497a | 147.01±15.78 | 132.13±10.53 | -19.57±1.15a |
| Diastolic (mmHg) | 87.33±11.69 | 78.47±5.36 | -9.88±0.61a | 89.36±10.54 | 78.70±6.22 | -13.02±0.95a |
SD, stdndard deviation; SE, standard error; PSA, prostate-specific antigen; IPSS, International Prostate Symptom Score; IIEF-EF, International Index of Erectile Function, erectile function domain; AMS, Aging Males' Symptoms score; HbA1c, glycosylated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CRP, C-reactive protein.
a:p<0.0001 vs. baseline. b:p=0.0021 vs. baseline.